NLS Pharmaceutics AG (NLSP)

NLS Pharmaceutics AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-12.17	-16.5	-11.95	-2.86	-5.45
Depreciation & Amortization	0.01	0.01	0.01	0	0
Share-Based Compensation	0.16	0.02	0	0	0
Other Operating Activities	2.31	2.58	-3	2.13	5.26
Operating Cash Flow	-9.68	-13.88	-14.94	-0.73	-0.19
Capital Expenditures	0	0	-0.04	0	0
Investing Cash Flow	0	0	-0.04	0	0
Share Issuance / Repurchase	0	14.57	14.55	0	0
Debt Issued / Paid	1.63	0.83	-2.1	1.19	0.67
Other Financing Activities	-	2	7.89	-0.69	-0.26
Financing Cash Flow	1.63	17.4	20.34	0.5	0.41
Exchange Rate Effect	0	-0	-0.02	0.1	-0
Net Cash Flow	-8.05	3.52	5.34	-0.13	0.21
Free Cash Flow	-9.68	-13.88	-14.98	-0.73	-0.19
Free Cash Flow Per Share	-0.25	-0.70	-1.26	-0.10	-0.03

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).